Re-treatment of interferon (IFN) plus ribavirin (RBV) nonresponders with peginterferon (PEG-IFN) Alfa-2A (40KD) (Pegasys) plus RBV and amantadine (AMA) or IFN Alfa-2A (Roferon-A) plus RBV and AMA. Interim results of a multicenter randomized study
S. Brillanti(University of Bologna), Maria Grazia Rumi(University of Milan), L. Cimino, Marcello Persico(University of Salerno), F. Fatuzzo, Luigi Fenoglio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Massimo Levrero(Northwest Medical Specialties), Giorgio Minoli(Ospedale Valduce), Alberto Civolani, Alessandra Mangia(Casa Sollievo della Sofferenza)
Cited by 2
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
|Oxidative Medicine and Cellular Longevity|2018|643